Macrocyclic lactones and uses thereof as modulators of purinergic receptors
US11058700B2 · kind B2 · utility
0Cited by
6References
5Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 28, 2016 |
| Grant date | Jul 13, 2021 |
| Priority date | — |
| Expiry date | Jun 2, 2037 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K35/768
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Described herein, inter alia, are macrocyclic lactones such as ivermectin and methods for their use in treating, for example, hyperproliferative disorders such as cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.